Cardiovascular event reduction vs new-onset diabetes during atorvastatin therapy

      As known, statins reduce cardiovascular (CV) events but increase the incidence of new-onset diabetes (NOD).   

    In a continuation of their research into atorvastatin and NOD risk, researchers at San Francisco General Hospital, San Francisco, found that, compared with low-dose therapy, treatment with atorvastatin 80 mg/day was not associated with an increased risk of NOD in patients with 0-1 NOD risk factors. Among patients with 2-4 NOD risk factors, atorvastatin 80 mg was associated with a 24% increase in NOD. Cardiovascular events were significantly reduced with atorvastatin 80 mg regardless of NOD risk factors.